{"filing":{"accession_number":"0001129928-26-000059","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"oncy-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000059/oncy-20260929.htm"},"events":[{"id":35666,"run_id":32861,"accession_number":"0001129928-26-000059","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Oncolytics disclosed publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating pelareorep's ability to convert immunologically inactive liver tumors to active, potentially susceptible to immunotherapy. This is a material operational/scientific milestone for a clinical-stage biotech company, supporting the therapeutic narrative and business development conversations around pelareorep as a backbone immunotherapy. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), it is clearly material to investors assessing the company's pipeline and competitive positioning, and fits best within operational_other as a significant research/development milestone.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39810,"accession_number":"0001129928-26-000059","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics disclosed publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating pelareorep's ability to convert immunologically inactive liver tumors to active, potentially susceptible to immunotherapy. This is a material operational/scientific milestone for a clinical-stage biotech company, supporting the therapeutic narrative and business development conversations around pelareorep as a backbone immunotherapy. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), it is clearly material to investors assessing the company's pipeline and competitive positioning, and fits best within operational_other as a significant research/development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:35:38.665837+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39810,"accession_number":"0001129928-26-000059","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics disclosed publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating pelareorep's ability to convert immunologically inactive liver tumors to active, potentially susceptible to immunotherapy. This is a material operational/scientific milestone for a clinical-stage biotech company, supporting the therapeutic narrative and business development conversations around pelareorep as a backbone immunotherapy. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), it is clearly material to investors assessing the company's pipeline and competitive positioning, and fits best within operational_other as a significant research/development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:35:38.665837+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-29"}]}